

# Javed Daniels

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9941444/publications.pdf>

Version: 2024-02-01

19  
papers

7,984  
citations

516710

16  
h-index

839539

18  
g-index

19  
all docs

19  
docs citations

19  
times ranked

4880  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1413-1424.	27.0	2,821
2	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2021, 385, 1451-1461.	27.0	2,143
3	SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. <i>Lancet</i> , The, 2020, 396, 819-829.	13.7	816
4	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2020, 382, 1883-1893.	27.0	753
5	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 326-336.	1.6	222
6	Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1279-1287.	7.1	205
7	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. <i>Circulation</i> , 2021, 144, 1284-1294.	1.6	195
8	Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function. <i>Circulation</i> , 2021, 143, 310-321.	1.6	168
9	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1270-1278.	7.1	155
10	Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. <i>European Heart Journal</i> , 2022, 43, 416-424.	2.2	144
11	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 1203-1212.	2.2	114
12	Left Atrium in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 1042-1049.	3.9	104
13	Redefining Heart Failure With a Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1761.	7.4	48
14	Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. <i>European Heart Journal</i> , 2022, 43, 3435-3446.	2.2	39
15	Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	20
16	Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2020, 13, e007829.	3.9	18
17	Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. <i>European Heart Journal</i> , 2021, 42, 4887-4890.	2.2	11
18	Kidney function assessment and endpoint ascertainment in clinical trials. <i>European Heart Journal</i> , 2022, 43, 1379-1400.	2.2	8

#	ARTICLE	IF	CITATIONS
19	Reply. JACC: Heart Failure, 2022, 10, 366-367.	4.1	0